Vera Therapeutics, Inc. Stock Price, News & Analysis

Vera Therapeutics (VERA) has secured a new $500 million credit facility with Oxford Finance, replacing its existing $50 million facility. The initial funding of $75 million is set for June 4, 2025. The new facility features a reduced interest rate of SOFR plus 4.95% (320 basis points lower), with $450 million available in five tranches. Key features include a $50 million draw option through 2026, $75 million tied to atacicept's accelerated approval in IgAN, two $50 million tranches post-approval, and $200 million at mutual discretion. The refinancing extends the interest-only period by 42 months and maturity by 41 months, eliminating 2026 principal payments. The company expects to submit a BLA for atacicept to the FDA in Q4 2025, targeting potential approval and launch in 2026.

Vera Therapeutics (NASDAQ: VERA) announced positive results from its ORIGIN Phase 3 trial of atacicept for treating IgA nephropathy (IgAN) in adults. The trial met its primary endpoint with atacicept achieving a significant 46% reduction in proteinuria from baseline and 42% reduction compared to placebo at week 36 (p<0.0001). The safety profile was favorable and comparable to placebo. Based on these promising results, Vera plans to submit a Biologics License Application (BLA) for accelerated approval to the FDA in Q4 2025, potentially leading to approval and commercial launch in 2026. The ORIGIN 3 trial, involving 431 adults, continues in a placebo-controlled manner to evaluate kidney function changes over two years, with final results expected in 2027.

Vera Therapeutics (NASDAQ: VERA) announced inducement awards granted to eleven new employees on May 5, 2025. The awards include non-qualified stock options to purchase 111,750 shares of Class A common stock and restricted stock units (RSUs) for 62,575 shares. The stock options have an exercise price of $25.53 per share, based on VERA's closing price on May 5.

The stock options will vest over 4 years, with 25% vesting on the first anniversary and the remainder vesting monthly over 36 months. The RSUs will vest over 4 years, with 25% vesting annually starting May 20, 2025. Both awards are contingent on continued employment with Vera.

Vera Therapeutics (NASDAQ: VERA) provided its Q1 2025 business update, highlighting significant progress in its atacicept development program. The company is approaching a crucial milestone with upcoming primary endpoint results from the pivotal Phase 3 ORIGIN trial for IgA Nephropathy (IgAN) in Q2 2025, followed by planned BLA submission to FDA in Q4 2025.

Financial results showed a net loss of $51.7 million ($0.81 per share) compared to $28.4 million ($0.56 per share) in Q1 2024. The company maintains a strong financial position with $589.8 million in cash and equivalents, deemed sufficient to fund operations through potential approval and U.S. commercial launch.

Vera has expanded its atacicept development program across multiple autoimmune kidney diseases and acquired rights to VT-109, a novel fusion protein targeting BAFF and APRIL.

Vera Therapeutics (VERA) announced inducement awards granted by its Compensation Committee on April 3, 2025, to sixteen new employees. The awards include:

• Non-qualified stock options to purchase 211,250 shares of Class A common stock at $22.74 per share
• Restricted stock units (RSUs) for 105,125 shares of Class A common stock

The stock options will vest over four years, with 25% vesting on the first anniversary and the remaining vesting monthly over 36 months. RSUs will vest over four years, with 25% vesting annually starting May 20, 2025. Both awards are subject to continued employment and the terms of the Inducement Plan.

Vera Therapeutics (NASDAQ: VERA) has announced the completion of full enrollment in its pivotal ORIGIN Phase 3 trial for atacicept in IgA Nephropathy (IgAN) patients, with 431 participants. The company expects to release the 36-week primary efficacy endpoint data this quarter (2Q 2025).

The trial is evaluating atacicept's safety and efficacy in IgAN patients with persistent proteinuria at high risk of disease progression. Participants receive weekly 150 mg subcutaneous injections of atacicept or placebo for 104 weeks, followed by a 52-week open-label extension.

Following positive long-term results from the ORIGIN Phase 2b trial, which showed sustained reductions in Gd-IgA1, hematuria, proteinuria, and stabilized kidney function through 96 weeks, Vera plans to submit a Biologics License Application (BLA) for accelerated approval to the FDA in 2H 2025, targeting a potential commercial launch in 2026.

Vera Therapeutics (VERA) announced the granting of inducement awards to nine new employees on March 6, 2025. The awards, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), include:

- Non-qualified stock options to purchase 51,500 shares of Class A common stock at $29.30 per share
- Restricted stock units (RSUs) for 25,750 shares of Class A common stock

The stock options will vest over four years, with 25% vesting on the first anniversary and the remainder monthly over 36 months. The RSUs will vest over four years, with 25% vesting annually starting May 20, 2025. Both awards are contingent on continued employment with Vera.

Vera Therapeutics (Nasdaq: VERA), a late clinical-stage biotechnology company specializing in immunological disease treatments, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston, MA from March 3-5, 2025.

The company's management team will engage in a fireside chat scheduled for Tuesday, March 4, 2025, at 9:10 AM EST. Additionally, they will conduct one-on-one investor meetings during the conference.

The fireside chat will be accessible via webcast, with a replay available for 90 days through the Investor Calendar section of Vera Therapeutics' website.

Vera Therapeutics (NASDAQ: VERA) provided its Q4 and full year 2024 business update, highlighting progress in its atacicept development program for IgA Nephropathy (IgAN). The company is on track to announce primary endpoint results from the pivotal Phase 3 ORIGIN trial in Q2 2025, with BLA submission planned for H2 2025.

Key developments include receiving FDA Breakthrough Therapy Designation for atacicept in IgAN and presenting positive 96-week eGFR stabilization data. Vera expanded atacicept's development pipeline to include multiple autoimmune kidney diseases and acquired rights to VT-109, a next-generation fusion protein.

Financial highlights show a net loss of $152.1 million ($2.75 per share) for 2024, compared to $96.0 million ($2.25 per share) in 2023. The company reported $640.9 million in cash and equivalents, strengthened by approximately $593.2 million in net proceeds from two equity financings in 2024.